Table 2. Meta-analysis of possible associations between PD-L1 expression and overall survival in patients with solid tumors.
| Group or subgroup | N | PD-L1(+/-) | 1 year OS | 3 year OS | 5 year OS | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| RR (95 % CI) | P | I2 | RR (95 % CI) | P | I2 | RR (95 % CI) | P | I2 | |||
| All studies | 59 | 6028/13976 | 2.02 (1.56-2.60) | <0.001 | 84 | 1.57 (1.34-1.83) | <0.001 | 91 | 1.43 (1.24-1.64) | <0.001 | 92 |
| Ethnic subgroups | |||||||||||
| Asian | 35 | 2211/4126 | 1.83 (1.61-2.08)* | <0.001 | 49 | 1.57 (1.39-1.77) | <0.001 | 74 | 1.44 (1.31-1.58) | <0.001 | 92 |
| Non-Asian | 24 | 3817/9850 | 1.98 (1.27-3.09) | 0.003 | 90 | 1.60 (1.18-2.17) |
0.003 | 95 | 1.39 (1.08-1.78) |
0.009 | 95 |
| Tumor origin | |||||||||||
| Gastrointestinal tumors | 24 | 1778/3206 | 2.12 (1.45-3.09) |
<0.001 | 86 | 1.52 (1.23-1.89) | <0.001 | 91 | 1.40 (1.17-1.67) | <0.001 | 91 |
| Other tumors | 35 | 4250/10770 | 1.79 (1.33-2.40) | <0.001 | 86 | 1.61 (1.30-1.98) | <0.001 | 92 | 1.47 (1.23-1.75) | <0.001 | 91 |
| Tumor type | |||||||||||
| Breast cancer | 5 | 1647/5677 | 1.80 (0.60-5.42) | 0.30 | 79 | 1.79 (0.77-4.19) | <0.18 | 95 | 1.80 (0.68-4.73) | <0.24 | 96 |
| Esophageal cancer | 4 | 187/252 | 1.90 (0.69-5.21) | 0.21 | 70 | 2.77 (1.78-4.30)* | <0.001 | 48 | 3.55 (2.63-5.65)* | <0.001 | 0 |
| Gastric carcinoma | 7 | 421/875 | 2.48 (1.80-3.41)* | <0.001 | 18 | 1.63 (1.43-1.87)* |
<0.001 | 32 | 1.45 (1.18-1.79) |
<0.001 | 79 |
| Hepatocellular carcinoma | 7 | 321/339 | 1.87 (1.01-3.46) |
0.04 | 78 | 1.40 (0.92-2.15) | 0.12 | 84 | 1.58 (1.11-2.25) |
0.01 | 83 |
| Lung cancer | 11 | 1396/2366 | 1.39 (0.69-2.81) | 0.36 | 88 | 1.17 (0.84-1.63) | 0.35 | 92 | 1.16 (0.86-1.57) | 0.32 | 93 |
| Pancreatic cancer | 3 | 61/131 | 3.43 (2.06-5.73)* | <0.001 | 15 | 1.48 (1.06-2.06)* | 0.02 | 0 | - | - | - |
| Merkel cell carcinoma | 3 | 107/272 | - | - | - | - | - | - | 1.01 (0.41-2.99) | 0.85 | 89 |
| urinary tract epithelial cell carcinoma | 4 | 197/655 | 6.24 (3.62-10.74)* | <0.001 | 0 | 3.43 (1.50-7.84) | 0.003 | 75 | 1.79 (0.86-3.70) | 0.12 | 82 |
| Oral squamous cell cancer | 5 | 380/537 | 1.05 (0.58-1.93) | 0.87 | 63 | 0.95 (0.72-1.26) | 0.72 | 55 | 1.07 (0.89-1.29)* | 0.45 | 0 |
| Renal cell carcinoma | 7 | 208/572 | 3.38 (2.13-5.39)* |
<0.001 | 24 | 4.14 (2.07-8.26) | <0.001 | 81 | 2.57 (1.46-4.52) |
<0.001 | 79 |
| Colorectal cancer | 3 | 788/1609 | 1.17 (0.27-5.06) | 0.84 | 95 | 0.94 (0.33-2. 67) | 0.90 | 96 | 1.16 (0.55-2.45) | 0.69 | 95 |
N, number of studies; OS, overall survival; RR, risk ratio; 95% CI, 95% confidence interval
* These meta-analyses were performed using a fixed-effects model. All other meta-analyses were performed using a random-effects model.